Saloni’s work brought the first-ever approved treatment to address symptoms of agitation associated with dementia due to Alzheimer’s disease. She has also engaged with members of Congress and administration staff to help drive awareness of the disease. Additionally, she has advocated for policy changes that are reflective of the evolving treatment landscape.
Brendan actively engages with external stakeholders to support our industry and demonstrate the value of our medicines to policymakers. He has educated state legislators on the drug supply chain and value-based insurance designs so that legislators have the knowledge to make informed decisions about legislation seeking to ensure patient access to affordable medicines.
Bob is an effective and accessible voice in highlighting the value of the pharmaceutical industry for policymakers and thought leaders. He has engaged federal, state and local officials at the site to help them better understand the challenges and opportunities of our industry. Bob is also involved and supportive of Pfizer’s Michigan Legislative Leaders program,
Phil is the Head of Chemistry and Pharmaceutical Sciences at Sunovion, but he also takes the time to participate in “State Researcher Fly-In Days.” Before these events, he takes the time to research the legislators he will meet and then develops the key points for each meeting. His research experience has impacted multiple meetings in
Jason Brandt is highly committed to civic action both personally and professionally. Through his role on the Sanofi US PAC Board, Jason advocates tirelessly for issues related to the healthcare industry. His passion for civic action is also clearly apparent in his leadership role as a Vice President of Sales in our Diabetes and Cardiovascular,
Oleg is a special type of researcher who can translate scientific concepts into themes and messages that resonate with non-scientists. He communicates the value of the critical work of pharmaceutical research in understandable, impactful ways to key elected officials, advocates and the public visiting Pfizer’s La Jolla, California site for many years now. Additionally, he
(Merck) – Steve advocates for the key role that pharmaceuticals play in the overall treatment of disease, where his goal is to drive business strategy and project planning. He has led the way for Merck to have significant process efficiencies, year over year cost reductions, working capital improvements, better value and innovation.
Going beyond his responsibilities as a researcher and leader, Miguel is extremely active in UCB’s public affairs and PAC activities. He is a leader in local/state activities and engagements with the Massachusetts Life Sciences Association and is focused on expanding UCB’s presence in the state. Furthermore, he has led a group of local, state and
Over the years, Dr. Chureen Carter has demonstrated her commitment to supporting and mentoring rising scientists. In her work building alliances that support evidence generation, Dr. Carter puts patients first, ensuring stakeholders understand the full value of the medicines they need. She has an exceptional ability to build bridges, whether with partners outside the organization
(Eli Lilly and Company) Pauline is a true patient advocate who believes in going beyond medicine to engage, educate and empower patients to be active in their own health care and improve overall outcomes. She identifies new ways to provide patients with timely, action-oriented resources on health and wellness and a variety of disease states.